Moderna, Inc.(MRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRNA Moderna, Inc.

Not Yet Opened 03-27 16:00:00 EDT

32.12

+0.64

+2.03%

盘后31.91

-0.21-0.65%

19:58 EDT

High32.57	Low31.25	Vol6.20M
Open31.54	D1 Closing31.48	Amplitude4.19%
Mkt Cap12.42B	Tradable Cap11.59B	Total Shares386.62M
T/O197.55M	T/O Rate1.72%	Tradable Shares360.75M
P/B1.14	ROE-28.77%	EPS-9.28
52wk High170.47	52wk Low29.25	P/E-3.46
Dividend0.00	Div.Yield0.00	ROA-15.14%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MRNA","market":"US","secType":"STK","nameCN":"Moderna, Inc.","latestPrice":32.12,"timestamp":1743105600000,"preClose":31.48,"halted":0,"volume":6198378,"hourTrading":{"tag":"盘后","latestPrice":31.91,"preClose":32.12,"latestTime":"19:58 EDT","volume":85577,"amount":2746997.4156,"timestamp":1743119936258},"delay":0,"floatShares":360753414,"shares":386622604,"eps":-9.28,"marketStatus":"Not Yet Opened","change":0.64,"latestTime":"03-27 16:00:00 EDT","open":31.54,"high":32.57,"low":31.25,"amount":197546199.441384,"amplitude":0.041931,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.28,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743148800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":31.48,"preHourTrading":{"tag":"盘前","latestPrice":31.54,"preClose":31.48,"latestTime":"09:29 EDT","volume":23714,"amount":751037.5332460001,"timestamp":1743082199999},"postHourTrading":{"tag":"盘后","latestPrice":31.91,"preClose":32.12,"latestTime":"19:58 EDT","volume":85577,"amount":2746997.4156,"timestamp":1743119936258},"volumeRatio":0.767847,"optionData":{"bulkOrders":[{"symbol":"MRNA","call":true,"expireDate":1743739200000,"strike":"36.0","timestamp":1743098522924,"price":0.22,"volume":22389,"amount":492558,"type":"+"},{"symbol":"MRNA","call":true,"expireDate":1743134400000,"strike":"38.5","timestamp":1743098522924,"price":0.01,"volume":22389,"amount":22389,"type":"-"}]},"impliedVol":0.806,"impliedVolPercentile":0.664},"requestUrl":"/m/hq/s/MRNA","defaultTab":"news","newsList":[{"id":"2522787582","title":"Jim Cramer: Moderna (MRNA) Blew It – But Their Cash Pile Could Save Them!","url":"https://stock-news.laohu8.com/highlight/detail?id=2522787582","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522787582?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 01:13","pubTimestamp":1743095630,"startTime":"0","endTime":"0","summary":"We recently published a list of Did Jim Cramer Nail or Miss These 14 Stocks?In this article, we are going to take a look at where Moderna, Inc.  stands against other stocks that Jim Cramer discusses.During the most recent episode of Mad Money, Jim Cramer described the current stock market as a “short sellers paradise,” offering an ideal moment for those betting against U.S. stocks. He pointed to an important deadline approaching: April 2nd when major tariffs are set to take effect.“We have a tariff deadline, beckoning a frightening deadline, actually April 2nd when the big tariffs are going to kick in, that means we’re headed for a moment of maximum fear as regular stock buyers either flee to the sidelines or move the money to Europe.”READ ALSO:Was Jim Cramer Right About These 23 Stocks?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-moderna-mrna-blew-171350551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","MNQmain","BK4534","BK4501","TQQQ","BK4139","BK4585","BK4532","NQmain","BK4548","USJW.SI","QLD",".IXIC","BK4568","TSYW.SI","SQQQ","USAW.SI","BK4551","PSQ","QID","MRNA","BK4588","BK4533"],"gpt_icon":1},{"id":"2522300357","title":"Moderna, Inc. (MRNA): Among Stocks To Trade Without Tariffs And Interest Rate Fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2522300357","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522300357?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 22:27","pubTimestamp":1743085678,"startTime":"0","endTime":"0","summary":"The Federal Reserve this week decided to keep interest rates unchanged, causing Donald Trump to lash out at the Fed chief. Jerome Powell seemed satisfied with the current state of the economy and the job market. What he did not like was the high uncertainty prevailing in the market.There’s a good reason why the uncertainty is causing problems for the Fed. It can’t reliably predict the future path of the economy if it doesn’t know what data to put in its models. This is pretty much the same problem that stock analysts have. With tariffs causing problems for American businesses, many investors are seeing their portfolios shrink.In such a scenario, we decided to look at stocks that are largely protected from both tariffs and interest rates. This ‘protection’ comes from the fact that their bull thesis is unlikely to be impacted by either of these factors.To come up with the list of stocks protected from tariffs and interest rates, we looked at the recently released list of Goldman Sachs’ t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moderna-inc-mrna-among-stocks-142758035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["US10Y.BOND","US7Y.BOND","MRNA","US6M.BOND","BK4585","BK4534","BK4551","US5Y.BOND","BK4548","BK4501","US30Y.BOND","BK4139","BK4535","BK4588","BK4568","US3Y.BOND","BK4532","BK4533","US2Y.BOND","BNTX","US12M.BOND"],"gpt_icon":0},{"id":"2522375940","title":"Citi Keeps Their Hold Rating on Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375940?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:56","pubTimestamp":1743073010,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham reiterated a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $40.00. The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-hold-rating-on-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-keeps-their-hold-rating-on-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNA"],"gpt_icon":0},{"id":"2522993353","title":"Moderna Inc. Stock Slips 7.0%, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522993353","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522993353?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:33","pubTimestamp":1743021180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. slid 7.0% to $31.48 on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 2.0% to 17,899.01 and Dow Jones Industrial Average falling 0.3% to 42,454.79.This was the stock's second consecutive day of losses.Moderna Inc. closed 81.5% short of its 52-week high of $170.47, which the company reached on May 24th.The stock underperformed when compared to some of its competitors, as Johnson & Johnson rose 0.4% to $161.72, Pfizer Inc. fell 1.3% to $25.21, and Gilead Sciences Inc. rose 1.28% to $109.27.Trading volume totaled 7.9 million, compared to the 50-day average of 11.9 million.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"gpt_icon":1},{"id":"2522337289","title":"As Vaccine Skepticism Mounts, Moderna's Business Grows More Precarious -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2522337289","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522337289?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 03:45","pubTimestamp":1743018300,"startTime":"0","endTime":"0","summary":"Moderna had a hoard of $19.3 billion in cash as the Covid-19 vaccine market peaked in early 2022. That cash pile has been getting smaller ever since. The biotech lost $3.6 billion in 2024, and analysts expect the company to lose another $4 billion this year, according to FactSet.Moderna says its cash on hand will be down to $6 billion by the end of this year, but the company has repeatedly tried to ease Wall Street fears: It is planning a long list of new product launches, and says it will stop losing money in 2028.Investor worries haven't gone away, namely the fear the company may soon need to raise capital, diluting the holdings of current shareholders.Shares are down 24% so far in 2025 and down more than 90% from its peak in 2021.Some Republican legislators, meanwhile, have pushed for federal health authorities to pull back approvals for mRNA-based vaccines, and Republicans have introduced legislation in seven state legislatures to limit the use of mRNA-based vaccines, according to ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDU","UPRO","SGXZ81514606.USD","LU2092627202.USD","NVDX","IVV","NVD2.UK","NVDY","SDS","LU1064131342.USD","NVD3.UK","LU2361045086.USD","SPXU","SPY","ESmain","SG9999001424.SGD",".SPX","LU0122379950.USD","NVD","BK4585","LU2471134796.USD","LU0823414551.USD","NVIW.SI","AMGN","BK4598","IE00BJJMRX11.SGD","IE00BMPRXQ63.HKD","NVDS","NVDS.UK","2NVD.UK","VOO","LU2244417387.USD","LU0823421333.USD","SH","LU2106854487.HKD","LU1839511570.USD","MRNA","NVDD","LU0109391861.USD","ABUS","LU0943347566.SGD","LU1037948541.HKD","OEX","SSO","SNVD.UK","OEF","LU1674673691.USD","3NVD.UK"],"gpt_icon":1},{"id":"2522333337","title":"BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT","url":"https://stock-news.laohu8.com/highlight/detail?id=2522333337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522333337?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 03:30","pubTimestamp":1743017417,"startTime":"0","endTime":"0","summary":"BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDTS&P 500 .SPXTop PerformersPercent ChangeCintas Corp CTAS.OQ+6.1%Molina Healthcare Inc MOH.N+4.4%Paychex Inc PAYX.OQ+4.3%Exelon Corp EXC.OQ+3.3%Constellation Brands Inc STZ.N+3.2%Bottom PerformersPercent ChangeSuper Micro Computer Inc SMCI.OQ-8.7%Moderna Inc MRNA.OQ-7.1%Tesla Inc TSLA.OQ-7.1%Arista Networks Inc ANET.N-6.7%Vistra Corp VST.N-6.4%As of 03:30 p.m., the S&P 500 .SPX lost 76.45 points, or 1.34%, to 5,699.12 and had posted 16 new 52-week highs and 6 new lows.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL5N3Q921D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4511","LU0234570918.USD","LU1435385759.SGD","EXC","LU2552382132.HKD","BK4597","IE00BVYPNW00.USD","LU0820561909.HKD","BK4169","LU1066051811.HKD","SG9999014005.SGD","SMCI","LU1366192091.USD","LU0106261372.USD","LU1861215975.USD","LU1429558221.USD","IE00BZ18W456.USD","LU2362540622.SGD","PAYX","LU1093756168.USD","IE00BMPRXR70.SGD","BK4585","ANET","BK4588","LU0251142724.SGD","LU0964807845.USD","LU0345769631.USD","LU0949170772.SGD","BK4574","STZ","LU2750360997.AUD","LU1066053197.SGD","MRNA","BK4081","MOH","TSYW.SI","TSLA","IE00BMPRXQ63.HKD","LU2750360641.GBP","LU2357305700.SGD","CTAS","LU0082616367.USD","BK4020","BK4533","VST","LU0345769128.USD","LU1066051498.USD","LU1839511570.USD","LU2362541273.HKD","IE0034235303.USD"],"gpt_icon":1},{"id":"1117005787","title":"Stock Track | Moderna Plummets Over 5% as Trump Administration Plans to Cut Vaccine Aid Support","url":"https://stock-news.laohu8.com/highlight/detail?id=1117005787","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117005787?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 23:20","pubTimestamp":1743002447,"startTime":"0","endTime":"0","summary":"Shares of Moderna, Inc.  plummeted 5.08% during Wednesday's trading session, significantly underperforming the broader market. The biotech company, known for its mRNA vaccine technology, faced a sharp selloff as investors reacted to concerning news in the vaccine industry.The stock's decline appears to be directly linked to reports that the Trump Administration plans to end support for Gavi, a global vaccine alliance. This decision could potentially impact the demand for vaccines, including thos","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MRNA"],"gpt_icon":0},{"id":"1100434532","title":"Stock Track | Moderna Plummets 5% as Trump Administration Plans to End Support for Vaccine Aid Organization","url":"https://stock-news.laohu8.com/highlight/detail?id=1100434532","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100434532?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 23:20","pubTimestamp":1743002444,"startTime":"0","endTime":"0","summary":"Shares of Moderna, Inc.  plummeted 5.08% in intraday trading on Wednesday, following reports that the Trump Administration plans to end support for Gavi, a key vaccine aid organization. The news has sent shockwaves through the pharmaceutical industry, particularly affecting companies heavily involved in vaccine production and distribution.The decision to withdraw support from Gavi could have significant implications for Moderna, a leading COVID-19 vaccine manufacturer. Gavi, the Vaccine Alliance","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Moderna Plummets 5% as Trump Administration Plans to End Support for Vaccine Aid Organization","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MRNA"],"gpt_icon":1},{"id":"2522860633","title":"Moderna Falls 4.1%, Novavax Down 2%; Report Says Trump Administration to End Support for Vaccine Aid Organization Gavi","url":"https://stock-news.laohu8.com/highlight/detail?id=2522860633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522860633?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 23:16","pubTimestamp":1743002161,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL3N3Q91A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4548","BK4139","BK4547","BK4533","BK4532","BK4534","MRNA","NVAX","BK4588","BK4501","BK4568","BK4551"],"gpt_icon":0},{"id":"2522880748","title":"6 ways the U.S. could get into real trouble from Trump's economic decisions","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880748","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880748?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 01:22","pubTimestamp":1742923320,"startTime":"0","endTime":"0","summary":"The stock market faces heightened risk of a 'black swan' event. President Donald Trump's arbitrary, personalized and quixotic policymaking is at odds with creating tax and regulatory reforms that foster investment and economic growth, and the predictability businesses and investors need to make sound decisions.As a result, recession risks are rising as American consumers become more pessimistic. In recent months, the richest 10% of U.S. households have accounted for an unusually large share of consumer spending, making the recent S&P 500 SPX correction even more worrisome.While stocks have rebounded somewhat, stock investors still have reason to be on watch for a \"black swan\" event - a destabilizing event that could turn a market correction into a full-scale rout.Black swans are unexpected, but investors can be aware of adverse conditions so they can prepare their portfolios accordingly. Here are six areas of the economy where the risk of a black swan is heightened:","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443622.USD","ARES","BK4566","IE00BKVL7J92.USD","BK4139","LU0006061336.USD","IE00BGHQF748.EUR","LU1280957306.USD","LU1670628061.USD","SG9999002224.SGD","LU1791807156.HKD","LU0310799852.SGD","IE00B19Z3581.USD","BLK","LU1509826696.USD","LU2505996681.GBP","LU0215105999.USD","LU0417517546.SGD","MRNA","IE00BJTD4V19.USD","LU1974910355.USD","IE00B1BXHZ80.USD","LU0211331839.USD","LU2552382132.HKD","LU1291159041.SGD","IE00BN8TJ469.HKD","LU0203347892.USD","LU0238689110.USD","LU0820562030.AUD","LU2237443382.USD","LU1363072403.SGD","BK4535","IE00BDCRKT87.USD","LU1988902786.USD","BK4568","BK4533","LU0048584097.USD","LU0742537680.HKD","LU1145028129.USD","LU2361044865.SGD","LU0868494617.USD","IE00B42XCP33.USD","IE0034235303.USD","LU2756315664.SGD","APO","IE00B1XK9C88.USD","LU1481011911.USD","LU1917777945.USD","LU0256863811.USD","LU1267930490.SGD"],"gpt_icon":0},{"id":"2522040077","title":"Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2522040077","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522040077?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering’s in-house drug development unit. \"Identification of this first lead candidate provides proof-of-concept for Logica as an engine to expedite and enhance drug discovery in a critical therapeutic area,\" said Professor Julie Frearson, PhD, Senior Vice President and Chief Scientific Officer, Charles River. \"Together with our partners at Valo Health and through our ongoing collaboration with Flagship’s Pioneering Medicines, we look forward to further leveraging the power of Logica to advance this program into lead optimization.\". Logica, the result of a strategic partnership between Charles River and Valo Health, is the industry’s first computation-powered, unified target-to-candidate offering. Logica leverages the integration of Valo Health’s AI-powered Opal Computational Platform and Charles River’s leading expertise in drug discovery and preclinical ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/charles-river-valo-health-identify-120000756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRNA","BK4530","BK4534","BK4532","BK4139","BK4121","BK4551","LU0390134368.USD","FHTX","SANA","BK4501","BK4585","BK4533","BK4548","BK4568","BK4588","CRL"],"gpt_icon":0},{"id":"2522023581","title":"How the stock market could suffer a 'black swan' event from Trump's policies","url":"https://stock-news.laohu8.com/highlight/detail?id=2522023581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522023581?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:05","pubTimestamp":1742900700,"startTime":"0","endTime":"0","summary":"6 ways the U.S. could get into real trouble from Washington's misguided economic decisions. President Donald Trump's arbitrary, personalized and quixotic policymaking is at odds with creating tax and regulatory reforms that foster investment and economic growth, and the predictability businesses and investors need to make sound decisions.As a result, recession risks are rising as American consumers become more pessimistic. In recent months, the richest 10% of U.S. households have accounted for an unusually large share of consumer spending, making the recent S&P 500 SPX correction even more worrisome.While stocks have rebounded somewhat, stock investors still have reason to be on watch for a \"black swan\" event - a destabilizing event that could turn a market correction into a full-scale rout.Black swans are unexpected, but investors can be aware of adverse conditions so they can prepare their portfolios accordingly. Here are six areas of the economy where the risk of a black swan is hei","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","LU2237443978.SGD","LU2264538146.SGD","LU1974910355.USD","IE0034235303.USD","LU0211328371.USD","LU0256863811.USD","LU1291159041.SGD","LU2552382132.HKD","ARES","APO","LU2430703251.USD","MRNA","IE00BDRTCR15.USD","IE00BFXG1179.USD","SG9999002232.USD","LU0208291251.USD","BK4566","LU0787776722.HKD","LU0106831901.USD","LU1481011671.HKD","LU1323610961.USD","IE00BZ1G4Q59.USD","BK4135","LU0976567544.SGD","LU0130102774.USD","LU0215105999.USD","LU1894683264.USD","IE00BVYPNV92.GBP","LU1084165304.USD","LU0689472784.USD","BLK","LU0070302665.USD","IE00B64PRP62.GBP","LU0731783048.USD","LU0211331839.USD","BK4533","IE00B3QW5Z07.USD","LU0310799852.SGD","LU0980610538.SGD","LU0238689110.USD","LU1989771016.USD","LU1914381329.SGD","BK4501","IE000M9KFDE8.USD","LU0971096721.USD","LU1551013425.SGD","LU1670628061.USD","LU1032466523.USD","IE00BWXC8680.SGD"],"gpt_icon":0},{"id":"2522700443","title":"Moderna Inc. Stock Advances 4.6%, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522700443","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522700443?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:35","pubTimestamp":1742848500,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. advanced 4.6% to $34.17 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.3% to 18,188.59 and the Dow Jones Industrial Average rising 1.4% to 42,583.32.This was the stock's second consecutive day of gains.Moderna Inc. closed 80.0% short of its 52-week high of $170.47, which the company achieved on May 24th.The stock outperformed some of its competitors, as Johnson & Johnson fell 0.2% to $163.29, Pfizer Inc. fell 0.5% to $26.14, and Gilead Sciences Inc. fell 0.32% to $106.74.Trading volume totaled 10.5 million, compared to the 50-day average of 12.0 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"gpt_icon":0},{"id":"2521717287","title":"Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2521717287","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521717287?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 17:01","pubTimestamp":1742806869,"startTime":"0","endTime":"0","summary":"Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna  and the best and worst performers in the therapeutics industry.Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine  and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.The 10 therapeutics stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 2.6%.In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results.Rising to global prominence during the COVID-19 pandemic with one of the first ef","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-rundown-moderna-nasdaq-mrna-090109783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1585245621.USD","LU0203347892.USD","LU2129689514.USD","SG9999003800.SGD","LU0965508806.USD","LU0158827948.USD","MRNA","IE0002141913.USD","USAW.SI","SRPT","LU2237443622.USD","BK4551","BK4533","LU0985320562.USD","BK4534","LU1244550577.SGD","NVIW.SI","ABBV","NQmain","IE00B3QW5Z07.USD","QLD","IE0009355771.USD","IE00BDGV0183.EUR","LU0965509010.AUD","IE00BFTCPJ56.SGD","BK4550","LENZ","LU1934455194.USD","IE00B19Z3B42.SGD","BMRN","SG9999015986.USD","LU0234572021.USD","TSYW.SI","LU1244550494.USD","NDAQ","BIIB","LU0456855351.SGD","LU0417517546.SGD",".IXIC","IE00B64PRP62.GBP","MNQmain","SQQQ","PSQ","USJW.SI","LU1267930490.SGD","TQQQ","LU2089283258.USD","QID","LU0234570918.USD"],"gpt_icon":1},{"id":"2521212607","title":"Moderna price target lowered to $33 from $40 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2521212607","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521212607?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 21:37","pubTimestamp":1742650662,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna  to $33 from $40 and keeps an Underweight rating on the shares, primarily due to more conservative RSV and influenza estimates. The firm now models 2025 RSV sales of about $148M, versus a prior estimate of about $210M, and for FY25 it now models total revenue of $2.1B, versus consensus of $2.2B and just above the $2B guidance midpoint, the analyst tells investors.Discover stocks' market position with detailed  competitor analyses.Read More on MRNA:Questions or Comments about the article?Craig-Hallum bullish on Personalis, initiates with a Buy. Early notable gainers among liquid option names on March 13th. Microsoft, Intel upgraded: Wall Street’s top analyst calls. Early notable gainers among liquid option names on March 10th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/moderna-price-target-lowered-33-133742858.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moderna-price-target-lowered-33-133742858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRNA"],"gpt_icon":0},{"id":"2521328542","title":"Moderna Is Maintained at Underweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2521328542","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521328542?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 00:32","pubTimestamp":1742574720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 12:32 ET (16:32 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"gpt_icon":0},{"id":"2521823653","title":"JPMorgan Cuts Price Target on Moderna to $33 From $40, Maintains Underweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2521823653","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521823653?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 23:15","pubTimestamp":1742570138,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has an average rating of hold and mean price target of $50.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MRNA"],"gpt_icon":0},{"id":"2521997174","title":"Moderna Inc. Stock Slips 2.6%, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2521997174","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521997174?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:35","pubTimestamp":1742502900,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. shed 2.6% to $32.45 on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 0.3% to 17,691.63 and Dow Jones Industrial Average falling 0.0% to 41,953.32.This was the stock's third consecutive day of losses.Moderna Inc. closed 81.0% short of its 52-week high of $170.47, which the company achieved on May 24th.The stock underperformed when compared to some of its competitors, as Johnson & Johnson remained unchanged, Pfizer Inc. fell 0.1% to $26.19, and Gilead Sciences Inc. fell 1.53% to $105.87.Trading volume totaled 5.6 million, compared to the 50-day average of 12.3 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"gpt_icon":1},{"id":"2520642987","title":"Bernstein Adjusts Price Target on Moderna to $39 From $45, Keeps Market Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2520642987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520642987?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 18:25","pubTimestamp":1742293542,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has an average rating of hold and mean price target of $51.10, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MRNA"],"gpt_icon":0},{"id":"2520638920","title":"Moderna (MRNA) Advances But Underperforms Market: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2520638920","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520638920?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 05:50","pubTimestamp":1742248217,"startTime":"0","endTime":"0","summary":"The most recent trading session ended with Moderna  standing at $34.71, reflecting a +0.26% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a rise of 0.85%, and the technology-dominated Nasdaq saw an increase of 0.31%.The the stock of biotechnology company has risen by 4.94% in the past month, leading the Medical sector's loss of 0.88% and the S&P 500's loss of 7.69%.Analysts and investors alike will be keeping a close eye on the performance of Moderna in its upcoming earnings disclosure. The company's earnings per share  are projected to be -$2.90, reflecting a 5.54% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $142.28 million, showing a 14.8% drop compared to the year-ago quarter.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$10.03 per share and a revenue of $2.2 billion, indicating changes of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moderna-mrna-advances-underperforms-market-215017035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRNA"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.modernatx.com","stockEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.1996},{"period":"6month","weight":-0.5115},{"period":"1year","weight":-0.7096},{"period":"ytd","weight":-0.2275}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.057743},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.012362},{"month":3,"riseRate":0.714286,"avgChangeRate":0.045993},{"month":4,"riseRate":0.666667,"avgChangeRate":0.143497},{"month":5,"riseRate":0.666667,"avgChangeRate":0.084117},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.035661},{"month":7,"riseRate":0.666667,"avgChangeRate":0.112447},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.073656},{"month":9,"riseRate":0.5,"avgChangeRate":-0.034163},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.046191},{"month":11,"riseRate":0.833333,"avgChangeRate":0.247575},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.061337}],"exchange":"NASDAQ","name":"Moderna, Inc.","nameEN":"Moderna, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Moderna, Inc.(MRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Moderna, Inc.(MRNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Moderna, Inc.,MRNA,Moderna, Inc.股票,Moderna, Inc.股票老虎,Moderna, Inc.股票老虎国际,Moderna, Inc.行情,Moderna, Inc.股票行情,Moderna, Inc.股价,Moderna, Inc.股市,Moderna, Inc.股票价格,Moderna, Inc.股票交易,Moderna, Inc.股票购买,Moderna, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Moderna, Inc.(MRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Moderna, Inc.(MRNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}